BioMed Bytes: MedaSorb Technologies (OTC:MSBT) , BioDelivery Sciences (NASDAQ:BDSI) Print
By Vinny Cassano   
Thursday, 22 October 2009 05:48

BioMedReports.COmShares of MedaSorb Technologies Corporation (OTC:MSBT) continued to run on Wednesday, closing at forty three cents, another thirty four percent to the upside. Wednesday's close makes the stock a near triple over the past five trading days and a seven-bagger over the past few months.


It's hard not to imagine a pullback after a run like that, but with a market cap of still under twenty million, I think that there is still more room for an additional speculative move to the upside based on the potential of the company's treatment for sever sepsis, Cytosorb, which is nearing the conclusion of a European trial.

A run to a dollar is plausible, in my opinion, as it gets closer to trial-results time, but I also suggest that investors who are holding from under ten take a little bit of profit on the way up; as what happened to AGEN re-iterated on Wednesday, nothing is a sure thing in the stock market.

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded down by nearly seven percent on Wednesday to close the day at $4.53 - a price that I still consider a good one to buy for those with a long term outlook.

The recently approved Onsolis is either about to launch, or already has launched - according to recent press releases - and as sales royalties start to roll in, BDSI should start trading to the upside.

I like BDSI as a long term growth pick, now that the company has an approved drug on the market, but I also see some short to mid term benefits based on the potential of Meda to register some immediate sales numbers.

I say 'buy the dips' with this one.

Disclosure: Long MSBT, BDSI
Visit Vinny's Blog VFC's Stock House




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus